CDK4 and liposarcoma: Several investigations have shown that CDK4 is overexpressed in cancer [35,36] and inhibiting CDK4 overexpression improves clinical treatment efficacy for breast cancer, melanoma, liposarcoma, and mantle cell lymphoma [37], which suggests that CDK4 could be a therapeutic target for cancer [38].